An interventional study of Aerobic eccentric intervention in Heart Failure with Preserved Ejection Fraction (HFPEF), Heart Failure with Reduced Ejection Fraction and Sarcopenia in Elderly, sponsored by Universita di Verona. Recruiting at 2 sites in Italy. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-14.
Sponsored by Universita di Verona · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 449 studies in Heart Failure with a site in Italy — 110 open to participants now, 130 under way, 18 of them phase 3. Heart Failure · Italy.
Among the 449 studies in Heart Failure with a site in Italy, this one is the 280th largest by planned enrollment of the 292 interventional ones that give a count, is one of 34 that started in 2024, is one of 132 with no phase, reaches primary completion later than 36 of the 129 other live ones, and was the 398th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →110 of the 449 studies in Heart Failure with a site in Italy are open now. Recruiting first, the newest first:
Niguarda Hospital · Sites in Italy
Ages 18+
AstraZeneca · Sites in Italy, United States, Argentina and 29 more countries
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Bayer · Sites in Italy, United States, Argentina and 20 more countries
Ages up to 18
Biotronik SE & Co. KG · Sites in Italy, Australia, Austria and 10 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 65 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
449 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 48 · Phase 3 85 · Phase 4 36
First in 1983; this study’s year is marked. 34 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 200 across the 292 interventional studies, 353 across the 152 observational. Of the 252 that completed or were terminated, 91 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
205 of 449 have an industry lead sponsor. The 10 most frequent:
Universita di Verona is the lead sponsor of 125 studies on the registry; 27 are open to participants now.
Universita di Verona has 3 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
36 of the studies in Heart Failure with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT03775161Vectorious Medical Technologies Ltd.V-LAP™ Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heaRt Failure | 2026-12 |
| NCT03994874Iperboreal Pharma SrlPeritoneal Ultrafiltration in Cardio Renal Syndrome. | 2026-12 |
Add all 36 to your calendar (.ics) → With an account.
Among the 449 studies in Heart Failure with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the safety, feasibility, and effectiveness of a 12-week eccentric exercise program for older adults with sarcopenia (muscle loss) or sarcopenic obesity and chronic heart failure (HF). The program aims to improve physical performance, muscle strength, and overall health without causing excessive strain on participants. Eccentric exercise has shown potential benefits for improving muscle function, and this study will help determine if it is a safe and effective option for individuals with heart failure and muscle loss.
Study Goals: The primary aim of this study is to test the feasibility and effectiveness of an eccentric exercise program for older adults with sarcopenia and CHF. The study will monitor physical performance, adherence to the program, and participants' ability to tolerate the exercise, as well as any impact on heart and muscle health.
Study Population: A screening visit will be scheduled to determine if individuals meet the criteria to participate in the study. During this visit, a detailed assessment will be made, and if eligible, participants will sign an informed consent form.
This study will assess whether a 12-week eccentric exercise program can help improve muscle strength, cardiovascular health, and overall physical performance in individuals with HF and sarcopenia. The program will involve exercising on an eccentric bike, which is designed to reduce strain on the heart while providing effective muscle strengthening benefits.
The study will use several physical performance tests to assess the impact of the exercise program, including:
Primary Outcomes
Feasibility Measures:
To be considered feasible, the study must meet these criteria: Recruitment >50%, Follow-up loss \<20%, Median attendance at training sessions >80%, Median adherence to prescribed volume >75%, Tolerance to RPE >70%.
Secondary Outcomes
Effectiveness Measures:
In addition to the physical performance tests mentioned, the study will assess muscle mass and fat distribution using DXA scans and BIA, providing a comprehensive view of body composition. Finally, the feasibility of remotely monitoring patients' physical activity to determine the impact of the intervention on their daily lives, specifically in terms of mobility and autonomy is assessed. To this end, patients will be asked to wear a set of five sensors (two on the ankles, two on the wrists, and one on the waist) for at least four days. The Axivity AX6 sensors, chosen for their light weight and long battery life, will collect data used to monitor time spent moving, sitting, and lying down, as well as to assess the quality of the recorded movements.
Training protocol overview Familiarization Phase Before starting the actual training program, patients will undergo a familiarization phase to allow them to adjust to the eccentric cycling equipment and understand the intensity of the exercises. This phase is critical for ensuring safety and optimizing adherence to the program.
Duration of Familiarization:
The familiarization phase will last for two weeks. The first week (sessions 4 and 5, conducted within the same week after medical screening and body composition testing) will focus on achieving an intensity that is perceived as "very light" (RPE 8-9) and maintaining it for 5-10 minutes.
The second week will aim for a light (RPE 10-11) to slightly heavy (RPE 10-13) intensity.
Muscle Pain Monitoring:
At the beginning and end of each familiarization session, patients will be asked to rate their muscle pain using the Visual Analog Scale (VAS) (0-10), where 0 represents no pain and 10 indicates unbearable pain. This ensures that any discomfort is monitored and managed appropriately, reducing the risk of muscle injury and enhancing adherence to the program.
Purpose of Familiarization:
This phase helps patients adapt to eccentric training, preventing unnecessary muscle damage and ensuring they are comfortable with the equipment and the level of exertion. It also serves to acclimatize the patients to the specific eccentric muscle contractions involved in the cycling exercise.
Exercise Prescription Trained kinesiologists will supervise the eccentric cycling sessions. Monitoring and adjusting exercise intensity based on heart rate (HR) and Rate of Perceived Exertion (RPE) will be central to ensuring safety and effectiveness throughout the intervention.
Intensity Monitoring: For participants on beta-blockers, maximum heart rate (HRmax) will be estimated using the formula: HRmax = 164 - (0.7 × age). For participants not on beta-blockers, HRmax will be calculated using: HRmax = 211 - (0.64 × age).
The HR and RPE will be continuously monitored to ensure participants are training within the prescribed intensity zones.
Target Intensity: The training intensity will be kept between light (57-64% of HRmax) and moderate/slightly heavy (64-76% of HRmax) levels. These ranges correspond to RPE values of approximately 10-14.
The intensity will vary within the session, with three different workloads: Light: RPE \~10, Moderate: RPE \~12, Slightly Heavy: RPE \~14
Session Structure: Each training session will be divided into three parts:
The duration of the central training phase will start at 20 minutes. Week 5-8 (Strengthening Phase): Training frequency will increase to three times per week. The duration of the central phase will increase progressively to 30 minutes. The intensity will gradually rise within the prescribed target range, increasing as the patients adapt.
Week 9-12 (Maximal Tolerable Load Phase): The frequency remains three times a week. The intensity will reach the higher end of the prescribed range, with patients performing the eccentric cycling at near-maximal intensities (RPE 14-15). Adjustments Every Two Weeks: Every two weeks, the workload will be reassessed and adjusted to ensure the target RPE is achieved and maintained. This will ensure continued progression and avoid plateauing.
Pedaling Frequency: Participants will be instructed to maintain a pedal cadence of 60 RPM (revolutions per minute) for each session. This will be a consistent cadence for the entire training phase.
Participants must meet all of the following criteria:
Sarcopenia as Class I: Skeletal muscle mass index (kg/m²)
Sarcopenia as Class II: Skeletal muscle mass index (kg/m²)
Obesity: waist circumference calculated in centimeters (cm)
Sarcopenia as Class II:
Exclusion Criteria:
Participants will be excluded if they meet any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Men and women aged 65 to 85 years, with stable heart failure (HF) (either preserved left ventricular ejection fraction (≥50%) or reduced ejection fraction (≤40%)). Eligibility requires classification as New York Heart Association (NYHA) class 1, 2, or 3, and meeting the diagnostic criteria for sarcopenia or sarcopenic obesity. Sarcopenic patients are classified by skeletal muscle mass index (kg/m²): class I (males ≤10.75, females ≤6.75) and class II (males ≤8.50, females ≤5.75). For sarcopenic obesity, the classifications are: class I (males 31.3-37%, females 22.1-27.6%) and class II (males \<31.5%, females \<22.1%). This arm will participate in a supervised eccentric cycling training program for three months. The intervention will include two training sessions per week in the first month, increasing to three sessions per week in the following two months.
Other: Aerobic eccentric intervention
This arm will participate in a supervised eccentric cycling training program for three months. The intervention will include two training sessions per week in the first month, increasing to three sessions per week in the following two months. Each session will consist of a warm-up (5 minutes), a main training phase (20-30 minutes), and a cool-down (5-10 minutes). The intensity of training will be gradually adjusted to maintain a perceived exertion rating (RPE) between light and moderate with a target heart rate zone (57-76% of HRmax). Pre- and post-training assessments will evaluate physical function through several tests, body composition and anthropometric indices, muscle strength of upper and lower limbs, questionnaires related to the overall health improvement. Finally, participants will also be monitored for daily physical activity through wearable sensors to track mobility and autonomy.
Recruitment and Retention Rate
The feasibility of implementing a three-month eccentric cycling training program will be assessed using the following individual measures: Recruitment and Retention Rate: % of enrolled participants who complete post-intervention assessments. (Units of measures: Percentage \[%\]) Criteria for Feasibility: • Recruitment\>50%
Time frame: Recruitment and retention will be assessed at baseline and week 12.
Session Attendance
The feasibility of implementing a three-month eccentric cycling training program will be assessed using the following individual measure: Session Attendance - Median number of training sessions attended relative to the total planned sessions. (Units of measures: Percentage \[%\]) Median session attendance\>80%
Time frame: Session attendance will be monitored weekly, with a final assessment at week 12.
Adherence to Training Volume
The feasibility of implementing a three-month eccentric cycling training program will be assessed using the following individual measures: Adherence to Training Volume - Median percentage of prescribed exercises completed relative to the total planned. (Units of measures: Percentage \[%\]) Criteria for Feasibility: • Median session attendance\>80%
Time frame: Adherence, will be monitored weekly, with a final assessment at week 12.
Program Tolerance
The feasibility of implementing a three-month eccentric cycling training program will be assessed using the following individual measure: Program Tolerance - Proportion of participants achieving the target Rate of Perceived Exertion (RPE) during sessions. (Units of measures: Percentage \[%\])
Time frame: Program tolerance will be monitored weekly, with a final assessment at week 12.
SARC-F questionnaire
score 0-10; The SARC-F questionnaire is a simple and widely used screening tool for sarcopenia, a condition characterized by the loss of muscle mass, strength, and function, often associated with aging and certain diseases.
Time frame: Pre and after 12 weeks
MNA questionnaire
The Mini Nutritional Assessment (MNA) is a validated screening tool designed to assess the nutritional status of older adults (aged 65 and above) and identify those at risk of malnutrition. (score 0-30)
Time frame: Pre and after 12 weeks
MMSE questionnaire
The Mini-Mental State Examination (MMSE) is a widely used cognitive screening tool designed to assess an individual's mental status and detect cognitive impairment, such as in dementia or mild cognitive impairment (MCI). (score 0-30).
Time frame: Only at PRE test
Minnesota Living with HF Questionnaire
The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a validated patient-reported outcome measure designed to assess the impact of heart failure (HF) on an individual's quality of life (QoL). It is widely used in clinical practice and research to evaluate the severity of symptoms, functional limitations, and emotional well-being in patients with heart failure (score 0-105).
Time frame: Pre and after 12 weeks
Physical Activity Level (IPAQ)
The International Physical Activity Questionnaire (IPAQ) is a widely used self-reported tool designed to assess physical activity levels in adults. It was developed by the World Health Organization (WHO) to provide a standardized method for evaluating physical activity across different countries and cultures. The IPAQ is commonly used in both research and public health settings to assess activity levels and promote physical activity. Total Physical Activity Score = Sum of the activity frequency (days per week) multiplied by the duration (minutes per day) for each activity intensity (vigorous, moderate, walking). The score is then categorized based on the thresholds above to identify low, moderate, or high activity levels.
Time frame: Only at PRE.
Weight
Measured by a scale. Values collected in kg.
Time frame: Pre and after 12 weeks
Height
Height measured by stadiometer. Values collected in meters (m).
Time frame: Only at PRE.
Body Mass Index
Body Mass Index (BMI) is a simple and widely used tool to assess body weight relative to height and categorize individuals into various weight status groups. While it does not directly measure body fat percentage, BMI is used as a general indicator of whether a person has a healthy weight for a given height. It is particularly useful for population-level assessments and as a quick screening tool in clinical settings. Calculated as weight (kg)/height² (m²), kg/m².
Time frame: Pre and after 12 weeks
Waist circumference
Waist circumference is a simple and widely used measure of abdominal fat. It is particularly important in assessing the risk of metabolic and cardiovascular diseases, as abdominal fat (specifically visceral fat) is associated with higher risks of conditions such as type 2 diabetes, hypertension, and heart disease. Measure in centimeters (cm).
Time frame: Pre and after 12 weeks
Hip circumference
Hip circumference is the measurement of the circumference around the widest part of the hips and buttocks, typically measured at the level of the greater trochanters (the bony prominence on the outer side of the hip). Measure in centimeters (cm).
Time frame: Pre and after 12 weeks
Calf circumference
Calf circumference is a simple measurement of the circumference around the widest part of the lower leg, specifically the gastrocnemius muscle area. It is often used in clinical and research settings to assess nutritional status, muscle mass, and vascular health, especially in individuals who may have muscle wasting or vascular conditions. Smaller calf circumference is often a marker of frailty and sarcopenia in older adults, which is linked to reduced physical function, increased risk of falls, and reduced mobility. Record the measurement: Measure in centimeters (cm).
Time frame: Pre and after 12 weeks
Muscle mass
Muscle Mass will be measured through a Dual-Energy X-ray Absorptiometry (DEXA). A DEXA scan is a highly accurate and widely used imaging technique primarily used to measure bone mineral density (BMD), but it can also provide detailed information about body composition, including muscle mass, fat mass, and bone mass. DEXA scans are commonly used in both clinical and research settings to assess muscle mass, fat distribution, and bone health. Values in kg.
Time frame: Pre and after 12 weeks
Fat Mass
Fat Mass will be measured through a Dual-Energy X-ray Absorptiometry (DEXA). A DEXA scan is a highly accurate and widely used imaging technique primarily used to measure bone mineral density (BMD), but it can also provide detailed information about body composition, including muscle mass, fat mass, and bone mass. DEXA scans are commonly used in both clinical and research settings to assess muscle mass, fat distribution, and bone health. Values in kg/%.
Time frame: Pre and after 12 weeks
Bone Density
Bone Density will be measured through a Dual-Energy X-ray Absorptiometry (DEXA). A DEXA scan is a highly accurate and widely used imaging technique primarily used to measure bone mineral density (BMD), but it can also provide detailed information about body composition, including muscle mass, fat mass, and bone mass. DEXA scans are commonly used in both clinical and research settings to assess muscle mass, fat distribution, and bone health. Values in g/cm².
Time frame: Pre and after 12 weeks
Short Physical Performance Battery
The Short Physical Performance Battery (SPPB) is a widely used clinical assessment tool designed to measure lower extremity function and physical performance in older adults. It is particularly useful for identifying early signs of frailty, functional decline, and mobility issues. The SPPB is a brief and reliable tool that evaluates multiple aspects of physical function through a series of simple tasks. The SPPB consists of three main tests: Gait Speed Test, Balance Test and Chair Stand Test. The SPPB provides a total score based on the performance of each test. The total score ranges from 0 to 12 points, with higher scores indicating better overall physical performance.
Time frame: Pre and after 12 weeks
Six Minute Walking Test
The 6-Minute Walk Test (6MWT) is a simple, widely used functional exercise test that measures an individual's endurance, aerobic capacity, and physical fitness. It is commonly used in clinical and research settings to assess the functional status and exercise tolerance of individuals. The person is instructed to walk continuously without running or stopping (unless necessary), and to pace themselves at a speed they feel comfortable with. The total distance walked in meters (m) is recorded at the end of the 6 minutes.
Time frame: Pre and after 12 weeks
Ten Meter Walking Speed
The Ten-Meter Walking Speed Test (10mWT) is a commonly used simple and reliable test to assess gait speed and walking ability in individuals, particularly older adults and those with health conditions affecting mobility. It provides valuable information about an individual's functional mobility and is often used in clinical and research settings to assess frailty, cognitive function, and the risk of falls. The subject is instructed to walk at their normal, comfortable pace over the 10-meter course. This test is performed without running and with the individual walking continuously from one end to the other. The time taken to cover the 10 meters is recorded, and the result is expressed in seconds (s) which can be used to assess walking speed in m/s.
Time frame: Pre and after 12 weeks
HandGrip
The Handgrip Strength Test is a simple and widely used measure of muscle strength, specifically the strength of the hand and forearm muscles. It is commonly used in clinical and research settings to assess overall muscle function, health, and frailty, particularly in older adults or individuals with conditions that may affect muscle strength and physical performance. The subject is asked to squeeze a handgrip dynamometer (a device designed to measure grip strength) as hard as possible for a few seconds for three attempts. The maximum force applied during the squeeze is recorded in kilograms (kg).
Time frame: Pre and after 12 weeks
Isometric Force
Isometric force testing with a Cybex dynamometer provides precise measurements of muscle strength, which are important for assessing an individual's functional ability, recovery, and rehabilitation progress. In this study, the subjects will perform maximal isometric contractions with the knee angle at 90 degrees. Two tests will be performed, separated by 2 minutes of recovery. The value will be expressed in Newton x Metre (Nm).
Time frame: Pre and after 12 weeks
Isokinetic Force
Isokinetic Force refers to the force exerted by a muscle during an isokinetic movement, where the velocity of the joint motion is kept constant throughout the range of motion. Isokinetic testing is often used to assess muscle strength, endurance, and power under controlled conditions. Isokinetic refers to a type of muscle contraction where the velocity of movement (the speed at which the limb moves) is kept constant by the testing equipment, regardless of the force the muscle is generating. This is achieved using isokinetic dynamometers, which can measure and control the speed of joint movement during the test (e.g., Cybex). These devices adjust resistance based on the muscle's output, ensuring that the joint velocity remains the same. In this study, the participants will perform two familiarization contractions and three evaluation contractions, both in extension and flexion, at the following speeds: 60, 90, 150, 180, and 210 °/s. The values will be recorded in Newton x Metre (Nm)
Time frame: Pre and after 12 weeks
Started Oct 2024 (actual). Primary completion is estimated for Sep 2025, 11 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 11 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.